Canadian Journal of Infectious Diseases and Medical Microbiology

Canadian Journal of Infectious Diseases and Medical Microbiology / 1997 / Article

Original Article | Open Access

Volume 8 |Article ID 106462 | https://doi.org/10.1155/1997/106462

Michael T Halpern, Ruth E Brown, Martine Drolet, Sonja V Sorensen, Lionel A Mandell, "Decision Analysis Modelling of Costs and Outcomes following Cefepime Monotherapy in Canada", Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 8, Article ID 106462, 9 pages, 1997. https://doi.org/10.1155/1997/106462

Decision Analysis Modelling of Costs and Outcomes following Cefepime Monotherapy in Canada

Received16 Apr 1996
Accepted10 Oct 1996

Abstract

OBJECTIVE: To evaluate the comparative cost of treatment and intermediate outcomes (percentage resistant organisms, days in hospital, etc) among cefepime and alternative parenteral antibiotics used for empiric monotherapy.DESIGN: Decision analysis model, based on published literature, clinical trial results and information from infectious disease clinicians.SETTING: A Canadian tertiary care hospital.INTERVENTION: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia.MAIN RESULTS: Cefepime treatment results in the lowest average cost per patient when used as initial empiric therapy for lower respiratory tract infections and for skin/soft tissue infections. Cefepime therapy is among the lowest cost treatments for the other infectious disease conditions and has the lowest cost for a weighted ‘average’ condition. Sensitivity analysis indicates that model results are most sensitive to duration of hospitalization.CONCLUSIONS: Initial empiric monotherapy with cefepime for serious infectious disease conditions may result in cost savings compared with alternative parenteral agents.

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views61
Downloads246
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.